Heparin Crisis Spurs Changes In FDA Emergency Response Policies
Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.
You may also be interested in...
Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate
Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.
Heparin Crisis Leads To New FDA Policy On Consulting Outside Experts
A Government Accountability Office report criticizing FDA's retention of outside experts on heparin contamination spurs disclosure and conflict-of-interest screening policies for emergency situations.
Elections Reshape FDA Oversight Scene On Capitol Hill
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.